Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.7% Higher – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price shot up 6.7% during mid-day trading on Wednesday . The stock traded as high as $0.55 and last traded at $0.49. 59,902,238 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 103,490,164 shares. The stock had previously closed at $0.46.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Saturday, January 25th. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Up 12.3 %

The company has a market capitalization of $78.68 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The company has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.28. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.